DDInter775 DDInter1397
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Fondaparinux {u} (Compound) causes {v} (Side Effect) Lightheadedness
Lightheadedness {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fondaparinux {u} (Compound) binds {v} (Gene) F10
F10 {u} (Gene) regulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Fondaparinux {u} (Compound) binds {v} (Gene) SERPINC1
SERPINC1 {u} (Gene) regulates {v} (Gene) EDEM1
EDEM1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) binds {v} (Gene) SLC6A4
SLC6A4 {u} (Gene) is bound by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) palliates {v} (Disease) endogenous depression
endogenous depression {u} (Disease) is palliated by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verteporfin
Verteporfin {u} (Compound) causes {v} (Side Effect) Retinal haemorrhage
Retinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fondaparinux {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Milnacipran {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Fondaparinux (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Paroxetine (Compound)
Fondaparinux (Compound) binds F10 (Gene) and F10 (Gene) regulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Paroxetine (Compound)
Fondaparinux (Compound) binds SERPINC1 (Gene) and SERPINC1 (Gene) regulates EDEM1 (Gene) and EDEM1 (Gene) is upregulated by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) palliates endogenous depression (Disease) and endogenous depression (Disease) is palliated by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin (Compound) causes Retinal haemorrhage (Side Effect) and Retinal haemorrhage (Side Effect) is caused by Paroxetine (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)